RE:MMED has been tanking lately.. The CEO has said publicly that he wants to keep patent filings and other small news quiet as to not tip the competition off to their new ideas, I would definitely hold my MMED shares and add more to other psychadelics companies, especially ATAI and CMPS. The latter, of which the former owns about 20%, is really the canary in the coal mine at the point in time: if their data from their phase IIb trial comes out as pointing to positive results, the whole sector including MMED will gain a lot of steam. Of course the reverse is also true, but based on what I've been hearing from scientists that I know, that seems unlikely as there is truly a lot of optimism about pyschadelics' potential in the community overall.